In addition, higher serum CLU levels in patients with prostate cancer were significantly associated with major prognostic factors such as high pretreatment serum PSA levels, advanced clinical stage, metastatic disease, and high percent of positive biopsy cores. The gene discussed is KLK3; the disease is Familial prostate cancer.